Глава 8

Гинкго билоба

Burns, N., J. Bryan, and T. Nettelbeck. 2006. Ginkgo biloba: no robust effect on cognitive abilities or mood in healthy young or older adults. Human Psychopharmacology 21(1): 27–37.

Dodge, H., T. Zitzelberger, B. Oken, et al. 2008. A randomized placebo-controlled trial of ginkgo biloba for the prevention of cognitive decline. Neurology 70(19): 1809–1817.

Hartley, D., L. Heinze, S. Elsabagh, et al. 2003. Effects on cognition and mood in postmenopausal women of 1- week treatment with Ginkgo biloba. Pharmacology Biochemistry and Behavior 75(3): 711–720.

Le Bars, P. L. 2003. Response patterns of EGb 761 in Alzheimer’s disease: influence of neuropsychological profiles. Pharmacopsychiatry 36(Suppl. 1): S50-55.

Le Bars, P. L., and J. Kastelan. 2000. Efficacy and safety of a Ginkgo biloba extract. Public Health Nutrition 3(4A): 495–499.

Mix, J., and W. Crews. 2002. A double- blind, placebo- controlled, randomized trial of Ginkgo biloba extract EGb 761 in a sample of cognitively intact older adults: Neuropsychological findings. Human Psychopharmacology 17(6): 267–277.

Nathan, P, S. Tanner, J. Lloyd, et al. 2004. Effects of a combined extract of Ginkgo biloba and Bacopa monniera on cognitive function in healthy humans. Human Psychopharmacology 19(2): 91–96.

Singh, В., Н. Song, X. Liu, et al. 2004. Dangshen (Codonopsis pilosula) and Bai guo (Ginkgo biloba) enhance learning and memory. Alternative Therapies in Health & Medicine 10(4): 52–56.

Гюперзин A

Aisen, P. 2007. A multi- center, double- blind, placebo- controlled therapeutic trial to determine whether natural huperzine A improves cognitive function. Clinical Trials.

Ved, H., M. Koenig, J. Dave, et al. 1997. Huperzine A, a potential therapeutic agent for dementia, reduces neuronal cell death caused by glutamate. NeuroReport 8(4): 963–967.

Xu, S., Z. Cai, Z. Qu, et al. 1999. Huperzine- A in capsules and tablets for treating patients with Alzheimer disease. Zhongguo Yao Li Xue Bao 20(6): 486–490.

Zhang, R., X. Tang Y. Han, et al. 1991. Drug evaluation of huperzine A in the treatment of senile memory disorders. Zhongguo Yao Li Xue Bao 12(3): 250–252.


Almeida Montes, L. G., M. P. Ontiveros Uribe, S. J. Cortes, et al. 2003. Treatment of primary insomnia with melatonin: A double- blind, placebo- controlled, crossover study. Journal of Psychiatry & Neuroscience 28(3): 191–196.

Cardinali, D. P, E. Gvozdenovich, and M. R. Kaplan. 2002. A doubleblind placebo-controlled study on melatonin efficacy to reduce anxiolytic benzodiazepine use in the elderly. Neuroendocrinology Letters 23(1): 55–60.

Dowling, G. A., R. L. Burr, E. J. Van Someren, et al. 2008. Melatonin and brightlight treatment for rest- activity disruption in institutionalized patients with Alzheimer’s disease. Journal of the American Geriatrics Society 56(2): 239–246.

Pillar, G., Е. Shahar, N. Peled, et al. 2000. Melatonin improves sleep-wake patterns in psychomotor retarded children. Pediatric Neurology 23(3): 225–228.

Smits, M. G., E. E. Nagtegaal, H. J. van der, et al. 2001. Melatonin for chronic sleep onset insomnia in children: A randomized placebo-controlled trial. Journal of Child Neurology 16(2): 86–92.


Crook, T., W. Petrie, C. Wells, et al. 1992. Effects of phosphatidyl-serine in Alzheimer’s disease. Psychopharmacology Bulletin 28: 61–66.

Hellhammer, J., E. Fries, C. Buss, et al. 2004. Effects of soy lecithin phos-phatidic acid and phosphatidylserine complex (PAS) on the endocrine and psychological responses to mental stress. Stress 7: 119–126.

Jorissen, B. L., F. Brouns, M. P. Van Boxtel, et al. 2001. The influence of soy- derived phosphatidylserine on cognition in age- associated memory impairment. Nutritional Neuroscience 4: 121–134.

Palmieri, G., R. Palmieri, M. R. Inzoli, et al. 1987. Double- blind controlled trial of phosphatidylserine in patients with senile mental deterioration. Clinical Trials 24: 73–83.


Balestreri, R., L. Fontana, and F. Astengo. 1987. A double- blind placebo controlled evaluation of the safety and efficacy of vinpocetine in the treatment of patients with chronic vascular senile cerebral dysfunction. Journal of the American Geriatrics Society 35(5): 425–430.

Bereczki, D., and I. Fekete. 1999. A systematic review of vinpocetine therapy in acute ischaemic stroke. European Journal of Clinical Pharmacology 55(5): 349–352.

Gulyas, В., С. Halldin, Р. Karlsson, et al. 1999. Cerebral uptake and metabolism of (11C) Vinpocetine in monkeys: PET studies, [in Hungarian] . Orvusi Hetilap 140(30): 1687–1691.

Vas, A., B. Gulyas, Z. Szabo, et al. 2002. Clinical and non- clinical investigations using positron emission tomography, near infrared spectroscopy and trans — cranial Doppler methods on the neuroprotective drug vinpocetine: A summary of evidences. Journal of Neurological Science 203–204: 259–262.